Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. Adding LVP modality to the Novum IQ Infusion Platform – which includes Baxter's syringe infusion pump (SYR) with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite – enables clinicians to util.

Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy

Amazon

Brookfield Renewable Partners

British American Tobacco

Comcast

Global Payments

HDFC Bank Limited

Humana

Rexford Industrial Realty

Truist Financial

VictoryShares Free Cash Flow ETF

The market is near record highs and NVDA is up 11 straight weeks. Yet, blue-chip coiled spring bargains are still bountiful. VFLO is the best deep value strategy ETF I've found. A great combo of deep value, quality, and growth. It's beating the S&P, value, and even the Nasdaq since inception. Combining ETFs with individual stocks is a great way to potentially achieve superior returns and yield than ETFs can achieve.

10 Coiled Spring Blue-Chip Bargain Buys

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host its Annual Meeting of Stockholders (the 2024 Annual Meeting) in a virtual format on Tuesday, May 7, 2024 at 9 a.m., Central Time, as disclosed in Baxter's proxy statement for the 2024 Annual Meeting. Online access to the 2024 Annual Meeting will begin at 8:45 a.m., Central Time. Stockholders will not be able to attend the 2024 Annual Meeting in person. The virtual format provides a conveni.

Baxter to Host Annual Meeting of Stockholders in Virtual Format

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024. Joel Grade, Baxter's chief financial officer, is scheduled to present at 4:00 p.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Friday, May 31, 2024. About Baxter Every day, millions of patients and caregivers.

Baxter to Present at Raymond James 45th Annual Institutional Investors Conference

Baxter International Inc. is a buy according to the analysis of price action, momentum, volume, and relative strength.

Baxter International Inc. Is A Buy (Technical Analysis)

Baxter to act as exclusive partner to Spectral for 10 years following PMX approval by U.S. FDA Baxter to act as exclusive partner to Spectral for 10 years following PMX approval by U.S. FDA

Spectral Medical Announces Amendment and Extension of Exclusive Supply and Distribution Agreement With Baxter Healthcare Corporation

Baxter International gets its buy rating from December reaffirmed, agreeing with today's bullish consensus from SA analysts and Wall Street. Positive drivers of the bull call include recent Q4 performance, declining debt, innovative new products in the pipeline, and dividend growth. Some weak spots are an unremarkable dividend yield or future revenue growth vs peers, as well as the nature of lengthy FDA approvals on products.

Baxter: Market-Leading Medical Supplier With Lots In The Pipeline

On February 8, 2024, Baxter International BAX Inc. (NYSE: BAX, $39.64, Market Capitalization: $20.1 billion), a global medtech leader, reported steady 4Q23 results, with a mild beat vs consensus on revenues and adjusted EPS. In 4Q23, consolidated revenue increased by 3.7% YoY to $3.9 billion (up 3% on a constant currency basis).

Baxter To Spin-Off Vantive (Kidney Care Unit) In July 2024

TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial.

Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients

Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.

Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand

Baxter International Inc. (BAX) Q4 2023 Earnings Call Transcript

The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Baxter (BAX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Baxter International (BAX) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.88 per share a year ago.

Baxter International (BAX) Tops Q4 Earnings and Revenue Estimates

Baxter International beat Wall Street expectations for fourth-quarter sales and profit on Thursday on strong demand for its medical devices and improvements in the supply chain environment.

Medical device maker Baxter beats sales and profit estimates on strong demand

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2023, and provided its financial guidance for full-year and first-quarter 2024. “Baxter's performance in 2023 reflects our building momentum as we executed upon several strategic initiatives designed to enhance our future performance, including the implementation of a new operating model, the sale of our BioPharma Solutions b.

Baxter Reports Fourth-Quarter and Full-Year 2023 Results

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Baxter (BAX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Countdown to Baxter (BAX) Q4 Earnings: Wall Street Forecasts for Key Metrics

Arista Networks

Brookfield Infrastructure Partners L.P.

Blackrock Inc

BYD Company Limited

BYD Co Ltd

Cameco

Celldex Therapeutics

Caesarstone

MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income.

MoneyShow's Best Investment Ideas For 2024: Part 2

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its fourth-quarter 2023 financial results on Thursday, February 8, 2024 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/etCeELhb to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.

Baxter to Host Fourth-Quarter 2023 Financial Results Conference Call for Investors

Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.

Reasons to Retain Baxter International (BAX) in Your Portfolio

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), an innovative leader in infusion therapies and technologies, announced the completion of the first phase of its intravenous (IV) bag recycling program pilot. Launched in conjunction with Northwestern Medicine, a premier integrated academic health system in Chicago, more than six tons (or 12,000 pounds) of polyvinyl chloride (PVC) IV bag waste — enough to cross the city of Chicago if bags were laid end-to-end — has been succ.

Baxter Advances First Intravenous (IV) Bag Recycling Pilot for U.S. Hospitals

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. José (Joe) E. Almeida, Baxter's chairman, president and chief executive officer, is scheduled to present at 10:30 a.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through Friday, July 5, 2024. About Baxter Every day, millions of.

Baxter to Present at 42nd Annual J.P. Morgan Healthcare Conference

Baxter International stock rated Buy, agreeing with Wall Street consensus. Tailwinds coming from positive revenue, earnings, and equity growth. Cheap share price below moving average combined with +3% dividend yield, for a company that returned to profitability.

Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its first report aligned with the Task Force on Climate-related Financial Disclosures (TCFD) recommendations, which were recently incorporated into the International Sustainability Standards Board Standards. The TCFD framework is designed to help improve climate-related disclosure that is relevant to Baxter's investors and other key stakeholders in the areas of governance, strategy,.

Baxter Publishes Task Force on Climate-Related Financial Disclosures (TCFD) Report and Is Named to Dow Jones Sustainability Index North America

DEERFIELD, Ill. & NEW YORK--(BUSINESS WIRE)--The Baxter International Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), and UNICEF, today announced a partnership to improve access to safe drinking water and sanitation in five water-challenged regions in Egypt. Supported by a $2.5 million grant from the Foundation, this three-year initiative aims to implement climate-smart water, sanitation and hygiene (WASH) programming for thousands of people in Upper Egypt's governora.

The Baxter International Foundation and UNICEF Partner to Expand Access to Safe Water and Sanitation in Egypt

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, announced today new data indicating Baxter's Sharesource remote patient management (RPM) digital platform, when used with an automated peritoneal dialysis (PD) system, is associated with a 77% reduction in risk of PD technique failure. Technique failure can be due to several factors and results in PD patients being switched to in-center dialysis. Additional key data.

News for Baxter Stock (BAX)